LOGIN
ID
PW
MemberShip
2023-12-07 13:14
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Opinion
[Reporter's view] Leader's responsibility
by
Feb 3, 2023 05:53am
One of the common grievances faced by employees of Korean subsidiaries of foreign companies is "Leader's irresponsibility." The representative of a Korean corporation is the head of a company in Korea, but he is one of the branch managers of many countries in the global view. Whether you like it or not, you have to follow the instructions of
Opinion
[Reporter¡¯s View] CDDC continues to raise controversy
by
Eo, Yun-Ho
Feb 1, 2023 05:54am
The Cancer Disease Deliberation Committee has settled as the highest threshold in reimbursement for anticancer drugs in Korea. This expert committee, which is a mandatory step for reimbursement in Korea, has put many anticancer drugs through an ordeal, to the extent that it was coined the ¡®wailing wall¡¯ to reimbursement in Korea. The co
Opinion
[Reporter's view] There's no instability in supply & demand
by
Lee, Tak-Sun
Jan 26, 2023 06:06am
Last-minute discussions between the NHIS and the pharmaceutical industry are underway regarding PVA of cold medicines, which increased their use due to COVID-19 last year. The consultation began when the government decided to correct the usage instead when the pharmaceutical industry suggested that cold medicines, which have increased their
Opinion
[Reporter¡¯s View] Our expectations for ADC technology
by
Jan 18, 2023 06:04am
Professor Park Yeon-hee of the Hematology and Oncology department at Samsung Medical Center who recently spoke at the press conference held to celebrate the launch of ¡®Enhertu¡¯ in Korea said, ¡°I have never seen such data in breast cancer.¡± This goes to show the superior efficacy of Enhertu in breast cancer. She added, ¡°During the Enhert
Opinion
[Reporter's view] The Pharmaceutical Bio-Innovation Committe
by
Kim, Jin-Gu
Jan 13, 2023 06:01am
President Yoon Suk Yeol is in his second year in office. President Yoon made various pledges to foster the pharmaceutical bio-industry when he was a candidate. The first of them was to set up a pharmaceutical bio-innovation committee. The pharmaceutical bio-industry was excited by his pledge. Expectations were high for the organization in cha
Opinion
[Reporter¡¯s View] Can new drug listings really be accelerat
by
Eo, Yun-Ho
Jan 11, 2023 05:59am
The measures to accelerate reimbursement listing of new drugs is expected to be implemented in earnest this year. However, the practicality of the measure &8211; on whether it will really accelerate drug listings &8211; remains in question. The health authorities made a preannouncement on the amendment of the pharmacoeconomic evaluation
Opinion
[Reporter¡¯s View] Decide whether to reimb diabetes combos
by
Lee, Tak-Sun
Jan 9, 2023 06:11am
Once again, discussions on expanding reimbursement to combination therapies to treat diabetes are at a standstill. The Ministry of Health and Welfare was unimpressed with the price reduction plans submitted by relevant companies under the assumption that reimbursements are expanded. This discussion, which had shown small progress only rec
Opinion
[Reporter's view] Expectations for Revlimid
by
Eo, Yun-Ho
Jan 3, 2023 05:41am
The maintenance therapy of Revlimid, a treatment for multiple myeloma, has been on the insurance benefit list since the new year of 2023 after more than four years of waiting. Revlimid maintenance therapy has simply had a lot of ups and downs. Since 2019, BMS Pharmaceutical Korea has actively carried out the registration process, but there ha
Opinion
[Reporter¡¯s View] Preserve the industry's willpower
by
Dec 21, 2022 06:05am
Even before the world was able to recover from the COVID-19 pandemic, a global economic recession has arrived to further the damage. With the rise in the price of raw materials, the price of every single consumable including food such as flour, sugar, and cooking oil, as well as fuel, utility bills, etc. have risen. Every day, you can see a
Opinion
[Reporter¡¯s View] Value of convenience in drug intake
by
Eo, Yun-Ho
Dec 13, 2022 06:07am
Taking the right medicine and taking the daily drug only once every month. This convenience in administration has become a competitivity in the pharmaceutical market. Although this had been more emphasized in the field of chronic diseases in the past, it is being emphasized in the field of anticancer drugs as well. The emergence of one-sh
1
2
3
4
5
6
7
8
9
10
>